Acadia Pharmaceuticals vs Axsome Therapeutics
ACAD and AXSM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACAD and AXSM compare
Axsome Therapeutics is the larger company, worth 2.3 times as much as Acadia Pharmaceuticals ($7.1B against $3.2B).
Axsome Therapeutics grew revenue faster over the last twelve months (56.9% versus 11.8% for Acadia Pharmaceuticals).
Acadia Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 33.4% compared with −24.7% at Axsome Therapeutics.
Acadia Pharmaceuticals scores higher on the StockData Score (16 against 8 for Axsome Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACAD | AXSM |
|---|---|---|
| Size and price | ||
| Market cap | $3.2B | $7.1B |
| Share price | $18.32 | $135.95 |
| Change, 1 year | −23.7% | −2.7% |
| Change, 5 years | −2.5% | 268% |
| Beta (5Y) | 0.53 | 0.87 |
| Employees | 798 | 500 |
| StockData Score | ||
| Total score | 16 (better) | 8 |
| Valuation score | 4 (better) | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 4 (better) | 2 |
| Health score | 6 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 8.3× | – |
| P/S | 2.8× (better) | 9.2× |
| P/B | 2.4× (better) | 85.5× |
| EV/EBITDA | 25.5× | – |
| P/FCF | 21.7× | – |
| FCF yield | 4.6% (better) | −1.0% |
| Fair value | $25.26 | – |
| Margin of safety | 27.5% | – |
| Growth | ||
| Revenue growth (TTM) | 11.8% | 56.9% (better) |
| Revenue growth, 5Y average | 19.4% | – |
| Net income growth (TTM) | 71.3% | – |
| EPS growth (TTM) | 66.2% | – |
| Profitability | ||
| Gross margin | 91.1% | 93.2% (better) |
| Operating margin | 7.6% (better) | −24.0% |
| Net margin | 33.4% (better) | −24.7% |
| FCF margin | 12.8% (better) | −9.3% |
| Return on equity | 35.7% (better) | −245% |
| Return on invested capital | 42.1% | – |
| Financial health | ||
| Debt / equity | 0.00 | 2.26 (better) |
| Current ratio | 3.39 (better) | 1.43 |
| Altman Z-score | 4.32 (better) | 4.21 |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Buyback yield | −1.5% | −0.50% (better) |
| Shareholder yield | −1.5% | −0.50% (better) |
| Ownership | ||
| Held by institutions | 97.9% | 73.8% |
| Held by insiders | 27.8% | 15.2% |
| Insider net buying, 12 months | −$2.5M (better) | −$113M |
| Short interest, % of float | 6.7% | 7.3% |
Go deeper
- ACAD stock overview
- ACAD income statement
- ACAD valuation and score
- AXSM stock overview
- AXSM income statement
- AXSM valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.